Exploring the Therapeutic Potential of Cannabigerol in Neurodegenerative Diseases

Abstract

Neurodegenerative disorders pose significant societal and individual burdens, marked by progressive degeneration of the nervous system. The limited efficacies of current treatments underscore the pressing need for innovative therapeutic approaches. Cannabigerol (CBG) is a cannabinoid derivative found in the plant genus Cannabis that is viewed as a molecule of therapeutic interest due to its unique pharmacological profile and interactions with the endocannabinoid system (ECS). This comprehensive review explores the therapeutic potential of CBG for the treatment of disorders of the nervous system, such as Alzheimers and Parkinsons disease. Preclinical investigations have revealed that the neuroprotective properties of CBG involve ECS modulation, promoting neuronal survival, and mitigating neuroinflammation and oxidative stress. However, it should be acknowledged that much of the research on the therapeutic potential of CBG is still in its early stages and primarily consists of in vitro and animal studies. Further clinical trials and research are needed to determine the efficacy and safety of CBG and the optimal dosing strategies required to treat neurodegenerative diseases. This review also explores the transformative potential of nanocarrier systems in CBG-centered therapies targeting neurodegenerative disorders and discusses the merits and demerits of various nanocarrier systems. This dual focus on the therapeutic potential of CBG and innovative distribution systems underscores the extent of the investigative work required to advance neurodegenerative disease management.